Dual-parameter liquid biopsy using plasma miR-21-5p and T cell LAIR-1 mean fluorescence intensity for hepatocellular carcinoma diagnosis in a high-risk Egyptian cohort

Table 10 Diagnostic performance of leading biomarkers in clinically challenging subgroups

Biomarker	Subgroup	AUC (95%CI)	Sensitivity (%)	Specificity (%)
hsa-miR-21-5p	Early-stage HCC (n = 33) vs cirrhosis	0.981 (0.949-1.000)	96.9	96.7
LAIR-1 MFI	Early-stage HCC (n = 33) vs cirrhosis	0.992 (0.975-1.000)	100.0	98.3
hsa-miR-21-5p	AFP-negative HCC (n = 22) vs cirrhosis	0.986 (0.961-1.000)	95.5	96.7
LAIR-1 MFI	AFP-negative HCC (n = 22) vs cirrhosis	0.998 (0.990-1.000)	100.0	98.3

Analysis based on the optimal cut-offs derived from the main cohort (Table 5). AFP: Α-fetoprotein; AUC: Area under the curve; CI: Confidence interval; HCC: Hepatocellular carcinoma; LAIR-1: Leukocyte-associated immunoglobulin-like receptor-1; MFI: Mean fluorescence intensity.